Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study.

ABSTRACT:

Background and purpose

Acamprosate is an anti-craving drug used for the pharmacotherapy of alcohol use disorder (AUD). However, only some patients achieve optimal therapeutic outcomes. This study was designed to explore differences in metabolomic profiles between patients who maintained sobriety and those who relapsed, to determine whether those differences provide insight into variation in acamprosate treatment response phenotypes.

Experimental approach

We previously conducted an acamprosate trial involving 442 AUD patients, and 267 of these subjects presented themselves for a 3-month follow-up. The primary outcome was abstinence. Clinical information, genomic data and metabolomics data were collected. Baseline plasma samples were assayed using targeted metabolomics.

Key

SUBMITTER: Ho MF 

PROVIDER: S-EPMC9177536 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature